Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Verfasst von: Buder-Bakhaya, Kristina [VerfasserIn]
• Verfasst von: Bender, Carolin [VerfasserIn]
• Titel: Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
• Verf.angabe: Jessica C. Hassel, Kristina Buder‐Bakhaya, Carolin Bender, Lisa Zimmer, Benjamin Weide, Carmen Loquai, Selma Ugurel, Alla Slynko & Ralf Gutzmer ; on behalf of the German Dermatooncology Group (DeCOG/ADO)
• Jahr des Originals: 2017
• Umfang: 10 S.
• Fussnoten: Gesehen am 10.09.2018 ; First published: 20 December 2017
• Titel Quelle: Enthalten in: Cancer medicine
• Jahr Quelle: 2018
• Band/Heft Quelle: 7(2018), 1, S. 95-104
• ISSN Quelle: 2045-7634
• DOI: doi:10.1002/cam4.1267
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1580832245

Abstract

Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One hundred and eighty patients with BRAF-mutant metastatic melanoma who had progressed on treatment with single-agent BRAFi from February 2010 to April 2015 were included in a retrospective data analysis focused on patterns of progression, treatment beyond progression (TBP) and subsequent treatments after BRAFi therapy. Analysis revealed that 51.1% of patients progressed with both new and existing metastases opposed to progression of only preexisting (28.3%) or only new (20.6%) metastases. Exclusive extracranial progression occurred in 50.6% of patients compared to both extra- and intracranial (29.4%) or sole cerebral progression (20%). Multivariable analyses demonstrated that single site progression and primary response to BRAFi were associated with improved progression-free survival. Progression with exclusively new or only existing metastases and a baseline Eastern Cooperative Oncology Group (ECOG) of 0 were associated with prolonged overall survival (OS). TBP had no significant impact on OS. Other subsequent treatments showed low efficacy with the exception of anti-PD-1 antibodies. In conclusion we identified specific patterns of progression which significantly correlate with further prognosis after progression on BRAFi treatment. In contrast to previously published data, we could not demonstrate a significant survival benefit for BRAFi TBP. Subsequent therapies had strikingly low efficacy except for PD-1 inhibitors.